Back to results
US 2023/0398185 A1Published application
Il-2/il-15r-beta-gamma agonist for treating non-melanoma skin cancer
AssigneeCytune Pharma
InventorsStefano FERRARA, Ulrich MOEBIUS, David BÉCHARD, Irena ADKINS, Nada PODZIMKOVA
Life of this patent
Estimating the term…
Abstract
The present invention relates to an interleukin-2/interleukin-15 receptor βγ (IL-2/IL-15Rβγ) agonist for use in the treatment of non-melanoma skin cancer. Further provided are dosing schemes for treating patients with non-melanoma skin cancer with an IL-2/IL-15Rβγ agonist.
Claims15
An interleukin 15 (IL-15)/interleukin-15 receptor alpha (IL-15Rα) complex for use in the treatment of non-melanoma skin cancer in a human patient, wherein the non-melanoma skin cancer is skin squamous cell carcinoma.
(canceled)
Dependencies are inferred from the claim text.